Allergan plc and its partner Perrigo Company plc announced today that Allergan has received U.S. Food and Drug Administration (FDA) approval for its Abbreviated New Drug Applications for three Mucinex® equivalent products.
- Mucinex® DM Regular Strength (guaifenesin 600mg and dextromethorphan 30mg)
- Mucinex® DM Maximum Strength (guaifenesin 1200mg and dextromethorphan 60mg)
- Mucinex® Maximum Strength (guaifenesin 1200mg)
Perrigo will begin
shipments of the products to its retail and wholesale customers in the
U.S in time for the 2016 cough and cold season. These products will be
packaged and marketed as store brands which will give consumers high
quality, value alternatives to these Mucinex® extended-release products.
Mucinex® Maximum Strength is an expectorant indicated to relieve
chest congestion and thin and loosen mucus. Sales for the last twelve
months were $73 million.
Mucinex® DM Regular and Maximum Strengths are expectorants indicated
to control coughs and thin and loosen mucus. Mucinex® DM Regular and
Maximum Strengths sales for the last twelve months were $67 million and $104 million, respectively.
